Document:

Exhibit 10.50

 

AMENDMENT TO INVESTMENT AGREEMENT

 

This Amendment to Investment
Agreement, dated as of May 19, 2020 (this “Amendment”), to that certain Investment Agreement, dated July 11,
2016, as amended (the “Agreement”), is entered into by and between HealthLynked Corp., a Nevada corporation,
with its principal executive offices at 1726 Medical Blvd Suite 101 Naples, FL 34110 (the “Company”), and Iconic
Holdings, LLC, a Delaware limited liability company, with its principal executive offices at 2251 San Diego Ave, #B150, San Diego,
CA 92110 (the “Investor” and together with the Company, the “Parties”). The purpose of this
Agreement is to further amend the terms of the Agreement.

 

WITNESSETH

 

WHEREAS, Section
8(ii) of the Agreement provides that the Agreement shall terminate upon the date which is thirty-six (36) months after the Effective
Date (as such term is defined in the Agreement) (the “Term”);

 

WHEREAS, pursuant
to Section 10.6 of the Agreement, the Agreement may only be amended by a written instrument signed by the Parties; and

 

WHEREAS, the
Parties desire to amend the Agreement to extend the Term of the Agreement.

 

NOW, THEREFORE, in
exchange for good and valuable consideration, the sufficiency of which are hereby acknowledged, and intending to be legally bound
hereby, the Parties hereby agree as follows:

 

1. Amendment.
Section 8 “Termination” of the Agreement is hereby deleted in its entirety and replaced with the following:

 

“This
Agreement shall terminate upon any of the following events:

 

		i.	when the Investor has purchased an aggregate of Three Million
Dollars ($3,000,000) in the Common Stock of the Company pursuant to this Agreement;

 

		ii.	on May 15, 2022; or

  

		iii.	at such time that the Registration Statement is no longer
in effect; or

 

		iv.	at any time at the election of the Company upon 15 days
written notice.

 

Any and all shares, or penalties,
if any, due under this Agreement shall be immediately payable and due upon termination of this Agreement.”

 

    -1-

     

    

 

2. Acknowledgement.
The Parties acknowledge that except as provided in this Amendment, all other terms and conditions of the Agreement, as amended,
remain in full force and effect. The Parties reaffirm, ratify and confirm their respective obligations, covenants and agreements
under the Agreement.

 

3. Miscellaneous.

 

(a) This Amendment may
be executed and delivered (including by facsimile, DocuSign, or .pdf transmission) in one or more counterparts, and by the different
parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together
shall constitute one and the same agreement.

 

(b) To the extent that
any provision of the Amendment needs to be waived or amended in order to allow the amendments made herein to be effective, such
provisions are hereby waived and/or amended to the extent necessary to allow for the amendments made herein to be effective.

 

(c) This Amendment and
any and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with
the laws of the State of California, without giving effect to the choice or conflict of law principles thereof.

 

[SIGNATURE PAGE FOLLOWS]

 

    -2-

     

    

 

IN WITNESS WHEREOF,
the undersigned have executed this Amendment as of the first date written above.

 

	 	HEALTHLYNKED CORP.
	 	 
	 	By:	/s/ George O’Leary
	 	 	Name:	George O’Leary
	 	 	Title:	Chief Financial Officer

 

	 	ICONIC HOLDINGS, LLC
	 	 
	 	By:	/s/ Michael Sobeck
	 	 	Name: Michael Sobeck
	 	 	Title:	Manager

 

 

-3-ex_187735.htm

Exhibit 10.1

 

 

 

May 18, 2020

 

Farshad Guirakhoo, Ph.D.

21 Ferry landing lane NW

Apt 1708

Atlanta GA 30305

 

Re: Revised Employment Arrangements

 

Dear Farshad,

 

We are disappointed that you have chosen to leave full-time employment as our Chief Science Officer, but we certainly understand your desire to move to Europe to be closer to your siblings.

As you know, your contributions to GeoVax over the last several years have been key to moving us forward.

 

We very much appreciate your willingness to continue as our Chief Science Officer on a part-time basis after June 4, 2020, which will be your last day of full-time employment. We will make appropriate accommodations to allow for the continuation of your service as CSO. Effective June 1, 2020, you will work remotely, given your planned relocation to Europe. With our recent collective experiences in working remotely during the COVID-19 pandemic, we believe this can be accomplished quite effectively.

 

It is my intention with this letter to outline what we have agreed to. It supplements and amends our existing agreements.

 

Continuation of Service as CSO During Part-Time Employment and Vacation Payout Period 

 

As you know, your continued services as Chief Scientific Officer are crucial to the Company’s success in the near future. Beginning June 1, your salary deferral will be discontinued, and your salary will be restored to its full amount ($20,833.33/mo., or $961.54 per day). The additional payment for housing assistance ($1,500.mo) will be eliminated.

 

We recognize that, as of May 31, you have accumulated 31 days of unpaid vacation. Beginning June 1, 2020, we will continue to pay your salary at your current rate, recognizing that you will devote 2 days per week to Company business, with the other 3 days per week being applied to a reduction of your accrued vacation. Under this arrangement, your accumulated vacation will be exhausted on August 10. At that time, we will mutually agree to the amount of time you will devote to Company business from that date forward and your salary will be adjusted proportionately, based on your annualized base salary (before deferrals). During this time, you will continue to be eligible for all Company benefit plans provided by Insperity. You will also be available, by remote access, as needed to support our efforts and assist us in the transition to a new CSO.

 

 

 GeoVax Labs, Inc.  –  1900 Lake Park Drive, Suite 380  –  Atlanta, Georgia  30080  USA  –  678.384.7220 tel  –  678.384.7281 fax – www.geovax.com

 

 

 

We understand that you have agreed to take a position as CSO of United Neuroscience (“UNS”)] effective June 5, 2020. We agree that, given the business of UNS, there is no apparent conflict of interest in your continuing to work for GeoVax. Please be sure to inform UNS of our arrangement and confirm to us that it will pose no problem from their point of view. We will expect you to manage your time so as to provide both UNS and GeoVax with the agreed-upon support.

 

Confirmation of Deferred Salary Amounts Owed – Pursuant to the Salary Deferral Agreement dated July 1, 2017, you have been deferring receipt of 25% of your base salary. Through May 31, the accumulated amounts owed to you under this arrangement will amount to $182,292. We confirm this amount as owed to you, and also confirm to you that, as previously contemplated, in lieu of a cash payment you will be entitled to ultimately receive the same form (cash, stock, etc.) and proportion of payout as all other officers and directors who have entered into similar arrangements. That will be confirmed in the general release we will ask for at the time of termination of your employment.

 

This Agreement may be terminated by either party upon 10 calendar days’ notice to the other party. If terminated prior to the exhaustion of accrued vacation pay discussed above, then the remaining unpaid vacation shall remain owed to you and paid in cash as salary continuance. We agree that your employment termination will be a voluntary termination by you without cause under your employment agreement with us, and that the above-described vacation pay and deferred salary will be all that is due. Except as specifically amended by this letter agreement, the employment agreement, as amended, and the salary deferral agreement remain in full force and effect. For example, we do not waive any of our rights, or your obligations, under Section 15 of your employment agreement.

 

If this letter sets forth our agreement, I would appreciate it if you would sign a copy and return it to me by email as soon as possible.

 

Thank you,

 

/s/ David A. Dodd

 

David A. Dodd

President & CEO

 

 

Agreed:

 

 

/s/ Farshad Guirakhoo                       

Farshad Guirakhoo, Ph.D.

Chief Scientific OfficerExhibit 10.1

 

Conversion Agreement

 

This Conversion
Agreement (this “Agreement”) is made and entered into as of May 22, 2020, by and between China Xiangtai
Food Co., Ltd., a Cayman Islands corporation (the “Company”), and YA II PN, Ltd. (the “Holder”),
holder of the Company’s Convertible Debentures (the “Debentures”).

 

Recitals

 

WHEREAS, on November 22, 2019,
the Company entered into a securities purchase agreement (as amended on December 18, 2019, the “Securities Purchase Agreement”)
with YA II PN, Ltd. to issue the Debentures in the aggregate principal amount of up
to $5,000,000.

 

WHEREAS, the Company also executed a
Registration Rights Agreement requiring the Company to file a registration statement on Form S-1 to register the shares of common
stock into which the Debentures may be converted for resale (the “Registration Statement”).

 

WHEREAS, the Registration Statement was initially
filed with the U.S. Securities and Exchanges Commission (the “SEC”) on December 19, 2019 and was declared effective
by the SEC on January 13, 2020.

 

WHEREAS, as of the date hereof, solely under the
convertible debenture issued on November 22, 2019 on the original principal amount of $2,000,000, the Company owes the Holder an
aggregate of $2,049,863, including principal due and accrued and unpaid interest (the “Obligation”).

 

NOW, THEREFORE, in consideration of the foregoing
and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the Company and the Holder
hereby agree as follows:

 

		1.	Conversion of the Obligation. 

 

		(a)	Conversion of the Obligation. The Holder hereby converts $750,000 of the Obligation into 750,000 shares of the Company's
common stock (the “Shares”) at a conversion price of $1.00 per share in full satisfaction of $750,000 of the
Obligation. The parties intend that the issuance of the Shares pursuant to the terms of this Agreement is an exempt issuance
under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on an exemption provided by
Sections 3(a)(9) of such act.  

 

		(b)	Closing Date. The Closing of this transaction shall occur at the office of Yorkville Advisors Global, LP at 1012 Springfield
Avenue, Mountainside, NJ 07092, as soon as possible after the date and time on which this agreement is executed (the “Closing
Date”).

 

		(c)	Deliveries. Subject to the satisfaction of the terms and conditions of this Agreement, on the Closing Date, the Company
shall issue the Shares to the Holder.

 

		2.	Representations and Warranties of the Holder

 

		(a)	Organization; Authority. Such Holder is an entity duly organized, validly existing and in good standing under the
laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents (as defined below) to which it is a party and otherwise to carry out its obligations
hereunder and thereunder. As used herein, “Transaction Documents” means, collectively, this Agreement, the Securities
Purchase Agreement, the Debentures, and each of the other agreements and instruments entered into by the Company or delivered by
the Company in connection with the transactions contemplated hereby and thereby, as may be amended from time to time.

 

    1

     

    

 

		(b)	Authorization, Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of
such Holder and shall constitute the legal, valid and binding obligations of such Holder enforceable against such Holder in accordance
with its terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors' rights and remedies.

 

		(c)	No Conflicts. The execution, delivery and performance by such Holder of this Agreement and
the consummation by such Holder of the transactions contemplated hereby will not (i) result in a violation of the organizational
documents of such Holder, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would
become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which such Holder is a party or (iii) result in a violation of any law, rule, regulation, order, judgment
or decree (including federal and state securities laws) applicable to such Holder, except, in the case of clauses (ii) and (iii)
above, for such conflicts, defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected
to have a material adverse effect on the ability of such Holder to perform its obligations hereunder.

 

		3.	Representations and Warranties of the Company

 

		(a)	Organization and Qualification. The Company and each of its Subsidiaries are entities duly formed, validly existing
and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authority to
own their properties and to carry on their business as now being conducted and as presently proposed to be conducted. The Company
and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction
in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to
the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse
Effect (as defined below). As used in this Agreement, “Material Adverse Effect” means any material adverse effect
on (i) the business, properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise)
or prospects of the Company and its Subsidiary, taken as a whole, (ii) the transactions contemplated hereby or in any of the other
Transaction Documents or any other agreements or instruments to be entered into by the Company in connection herewith or therewith
or (iii) the authority or ability of the Company to perform any of its obligations under any of the Transaction Documents. “Subsidiaries”
means any Person in which the Company, directly or indirectly, owns a majority of the outstanding capital stock having voting power
or holds a majority of the equity or similar interest of such Person, and each of the foregoing, is individually referred to herein
as a “Subsidiary”.

 

		(b)	Authorization; Enforcement; Validity. The Company has the requisite power and authority to enter into and
perform its obligations under this Agreement and the other Transaction Documents and to issue the Shares in accordance with the
terms hereof and thereof. The execution and delivery of this Agreement and the other Transaction Documents by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby including, without limitation, the issuance of
the Shares, have been duly authorized by the Company's board of directors and no further filing, consent or authorization is required
by the Company, its board of directors or its stockholders or other governmental body. This Agreement has been, and the other Transaction
Documents to which the Company is a party will be prior to the Closing, duly executed and delivered by the Company, and each constitutes
the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its respective terms,
except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors' rights and
remedies and except as rights to indemnification and to contribution may be limited by federal or state securities law.

 

    2

     

    

 

		(c)	Issuance and Delivery of the Shares. The Company hereby represents and warrants that the Shares, when issued by the
Company pursuant to Section 1, have been duly authorized and, when issued in compliance with the provisions of this
Agreement, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights, taxes, liens and
charges and other encumbrances with respect to the issue thereof with the Holder thereof being entitled to all rights accorded
to a holder of common stock and the issuance by the Company of the Shares, when issued by the Company pursuant to Section
1, will be exempt from registration under the Securities Act by virtue of Section 3(a)(9) thereof. The Shares will not bear
any restrictive legend and will be freely tradable without any restrictions or limitations under applicable securities laws, rules
and regulations. The Company agrees not to take any position contrary to this Section 3(c) for purposes of Section
3(a)(9) or Rule 144 of the Securities Act. The Company agrees to take all actions, including, without limitation, retaining legal
counsel to assist with the preparation of any necessary legal opinions, required to issue the Shares free of any restrictive legend
and to allow them to be freely tradeable on the Nasdaq Capital Market (“Nasdaq”), without the need for further
action by the Holder, except with respect to the delivery of any certificates, certifications or other similar reasonably necessary
assistance of the Holder required for such issuance or un-restriction.

 

		(d)	No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Shares)
will not (i) result in a violation of the memorandum of association, articles of association, by-laws, certificate of formation,
or other organizational documents of the Company or any of its Subsidiaries, or any capital stock or other securities of the Company
or any of its Subsidiaries, (ii) conflict with, or constitute a default under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including, without limitation, U.S. federal
and state securities laws and regulations, the securities laws of the jurisdictions of the Company's incorporation or in which
it or its subsidiaries operate and the rules and regulations of Nasdaq and including all applicable laws, rules and regulations
of the State of Nevada) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or
any of its Subsidiaries is bound or affected, except in the case of (ii) and (iii) for any conflict, default, right or violation
that would not reasonably be expected to result in a Material Adverse Effect.

 

    3

     

    

 

		(e)	Consents. The Company is not required to obtain any material consent from, authorization or order of, or make any filing
or registration with (other than any filings as may be required by any state securities agencies and any filings as may be required
by the Principal Market), any Governmental Entity (as defined below) or any regulatory or self-regulatory agency or any other Person
in order for it to execute, deliver or perform any of its obligations under or contemplated by the Transaction Documents, in each
case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which the
Company or any Subsidiary is required to obtain pursuant to the preceding sentence have been or will be obtained or effected on
or prior to the Closing Date, and neither the Company nor any of its Subsidiaries are aware of any facts or circumstances which
might prevent the Company or any of its Subsidiaries from obtaining or effecting any of the registration, application or filings
contemplated by the Transaction Documents. The Company is not in violation of the requirements of Nasdaq and has no knowledge of
any facts or circumstances which could reasonably lead to delisting or suspension of the Common Stock in the foreseeable future.
The Company has notified Nasdaq of the issuance of all of the Shares hereunder, which does not require obtaining the approval of
the stockholders of the Company or any other Person or Governmental Entity, and Nasdaq has completed its review of the related
Listing of Additional Share form. “Governmental Entity” means any nation, state, county, city, town, village,
district, or other political jurisdiction of any nature, federal, state, local, municipal, foreign, or other government, governmental
or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any
court or other tribunal), multi-national organization or body; or body exercising, or entitled to exercise, any administrative,
executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the
foregoing, including any entity or enterprise owned or controlled by a government or a public international organization or any
of the foregoing.

 

		(f)	Acknowledgment Regarding Holder's Purchase of Shares. The Company acknowledges and agrees that the Holder is acting
solely in the capacity of an arm's length purchaser with respect to the Transaction Documents and the transactions contemplated
hereby and thereby and that no Holder is (i) an officer or director of the Company or any of its Subsidiaries, (ii) to its knowledge,
an "affiliate" (as defined in Rule 144 promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule
144”)) of the Company or any of its Subsidiaries or (iii) to its knowledge, a “beneficial owner” of more
than 10% of the shares of Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Company further acknowledges
that no Holder is acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Holder
or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and
thereby is merely incidental to such Holder's purchase of the Shares. The Company further represents to the Holder that the Company's
decision to enter into the Transaction Documents to which it is a party has been based solely on the independent evaluation by
the Company and its representatives.

 

		(g)	No Integrated Offering. None of the Company, its Subsidiaries or any of their affiliates, nor any Person acting on their
behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under
circumstances that would adversely affect reliance by the Company on Section 3(a)(9) of the Securities Act or require registration
of any of the Shares under the Securities Act or, to the knowledge of the Company, cause the transactions contemplated hereby to
be integrated with prior offerings of common stock by the Company for purposes of the Securities Act.

 

    4

     

    

 

		(h)	SEC Documents; Financial Statements. During the two (2) years prior to the date hereof, the Company has timely
filed all reports, schedules, forms, proxy statements, statements and other documents required to be filed by it with the SEC pursuant
a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial
statements of the Company included in the SEC Documents complied in all material respects with applicable accounting requirements
and the published rules and regulations of the SEC with respect thereto as in effect as of the time for the periods then ended
(subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either individually
or in the aggregate). The reserves, if any, established by the Company or the lack of reserves, if applicable, are reasonable based
upon facts and circumstances known by the Company on the date hereof and there are no loss to the reporting requirements of the
Securities Exchange Act of 1934, as amended (the “1934 Act”) (all of the foregoing filed prior to the date hereof
and all exhibits and appendices included therein and financial statements, notes and schedules thereto and documents incorporated
by reference therein being hereinafter referred to as the “SEC Documents”). The Company has delivered or has
made available to the Holder or its respective representatives true, correct and complete copies of each of the SEC Documents not
available on the EDGAR system. As of their respective dates, the SEC Documents complied in all material respects with the requirements
of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the
SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the
SEC Documents complied in all material respects with applicable accounting requirements and the published rules and regulations
of the SEC with respect thereto as in effect as of the time of filing. Such financial statements have been prepared in accordance
with U.S. generally accepted accounting principles (“GAAP”), consistently applied, during the periods involved
(except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim
statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material
respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the
periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material,
either individually or in the aggregate). The reserves, if any, established by the Company or the lack of reserves, if applicable,
are reasonable based upon facts and circumstances known by the Company on the date hereof and there are no loss contingencies that
are required to be accrued by the Statement of Financial Accounting Standard No. 5 of the Financial Accounting Standards Board
which are not provided for by the Company in its financial statements or otherwise. No other information provided by or on behalf
of the Company to the Holder which is not included in the SEC Documents (including, without limitation, information in the disclosure
schedules to this Agreement) contains any untrue statement of a material fact or omits to state any material fact necessary in
order to make the statements therein not misleading, in the light of the circumstance under which they are or were made. The Company
is not currently contemplating to amend or restate any of the financial statements (including, without limitation, any notes or
any letter of the independent accountants of the Company with respect thereto) included in the SEC Documents (the “Financial
Statements”), nor is the Company currently aware of facts or circumstances which would require the Company to amend or
restate any of the Financial Statements, in each case, in order for any of the Financials Statements to be in compliance with GAAP
and the rules and regulations of the SEC. The Company has not been informed by its independent accountants that they recommend
that the Company amend or restate any of the Financial Statements or that there is any need for the Company to amend or restate
any of the Financial Statements.

 

		(i)	Shell Company Status. The Company is not, and has never been, an issuer identified in, or subject to, Rule 144(i).

 

    5

     

    

 

		4.	Miscellaneous.

 

		(a)	Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement
and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to
any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits
to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication
of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated
hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient
forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at
the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking other
legal action against the Company in any other jurisdiction to collect on the Company's obligations to such Holder or to enforce
a judgment or other court ruling in favor of such Holder. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO,
AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR
IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

		(b)	Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party. In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document
format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original
thereof.

 

		(c)	Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of
this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally;
(ii) upon receipt, when sent by email (provided confirmation of transmission is electronically generated and kept on file by the
sending party); or (iii) one (1) Business Day after deposit with an overnight courier service with next day delivery specified,
in each case, properly addressed to the party to receive the same. The addresses and e-mail addresses for such communications shall
be:

 

	If to the Company, to:	CHINA XIANGTAI FOOD CO., LTD.
	
         

         

         

         

         

         

         

        With a copy to:
	
        Xinganxian Plaza, Building B, Suite 21-1

        Lianglukou, Yuzhong District

        Chongqing, People’s Republic of China 400800

        Attention: Chief Executive Officer

        Telephone: +86 (023) 86330158

        Email: ir@cqplinfood.com

         

        Ortoli Rosenstadt LLP

        366 Madison Avenue, 3rd Floor

        New York, NY 10017

        Telephone:  212-588-0022

        Attention:  William Rosenstadt

        E-Mail:  wsr@orllp.legal

 

    6

     

    

	 	 
	 If to the Holder, to:	
        YA II PN, Ltd.

        c/o Yorkville Advisors Global, LP

        1012 Springfield Avenue

        Mountainside, NJ 07092

        Email: Legal@yorkvilleadvisors.com

	 	 
	With copy to:	
        David Fine, Esq.

        c/o Yorkville Advisors Global, LP

        1012 Springfield Avenue

        Mountainside, NJ 07092

        Email: legal@yorkvilleadvisors.com

 

		(d)	Entire Agreement, Amendments. This Agreement supersedes all other prior oral or written agreements between the Holder,
the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement
and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein
and therein and, except as specifically set forth herein or therein, neither the Company nor the Holder makes any representation,
warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than
by an instrument in writing signed by the party to be charged with enforcement.

 

 

[REMAINDER
PAGE INTENTIONALLY LEFT BLANK]

 

 

 

 

    7

     

    

 

IN WITNESS WHEREOF, the
Holder and the Company have caused their respective signature page to this Conversion Agreement to be duly executed as of the date
first written above.

 

	 	COMPANY:
	 	 
	 	CHINA XIANGTAI FOOD CO., LTD.
	 	 
	 	By:	/s/ Zeshu Dai
	 	Name: 	Zeshu Dai 
	 	Title:	Chairwoman

 

 

 

	 	HOLDER:
	 	 
	 	YA II PN, LTD.
	 	 	 	 
	 	By:	Yorkville Advisors Global, LP
	 	Its:	Investment Manager
	 	 	 	 
	 	 	By:  Yorkville Advisors Global II, LLC
	 	 	Its:   General Partner
	 	 	 	 
	 	 	By:	/s/ Matt Beckman
	 	 	Name:	Matt Beckman
	 	 	Title:	Managing Member

 

 

    8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]